2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

2-D : two-dimensional 3-D : three-dimensional 5-FU : 5-fluorouracil ACE : angiotensin-converting enzyme ARB : angiotensin II receptor blocker ASE : American Society of Echocardiography BNP : B-type natriuretic peptide CABG : coronary artery bypass graft CAD : coronary artery

[1]  Lara A. Kahale,et al.  Anticoagulation for people with cancer and central venous catheters. , 2018, The Cochrane database of systematic reviews.

[2]  E. Perez,et al.  Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Perez,et al.  Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Lipshultz,et al.  Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Michael Hauptmann,et al.  Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Morten Wang Fagerland,et al.  Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol , 2016, European heart journal.

[7]  Andrea Mazzanti,et al.  2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.

[8]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[9]  Baris Gencer,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .

[10]  S. Russell,et al.  Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866) , 2015 .

[11]  S. Devlin,et al.  Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy , 2015 .

[12]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the diagnosis and management of pericardial diseases , 2015, European heart journal.

[13]  M. Piccart-Gebhart,et al.  Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. , 2015, European journal of cancer.

[14]  K. Huynh.  Acute coronary syndromes: Bivalirudin versus heparin for ACS , 2015, Nature Reviews Cardiology.

[15]  J. Moslehi,et al.  Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Barac,et al.  Burgeoning Cardio-Oncology Programs: Challenges and Opportunities for Early Career Cardiologists/Faculty Directors. , 2015, Journal of the American College of Cardiology.

[17]  L. Tryggvadottir,et al.  Cardiovascular disease in Adult Life after Childhood Cancer in Scandinavia: A population‐based cohort study of 32,308 one‐year survivors , 2015, International journal of cancer.

[18]  D. Lenihan,et al.  Cardio-oncology: a new discipline in medicine to lead us into truly integrative care. , 2015, Future cardiology.

[19]  S. Lipshultz,et al.  Cardiac complications in childhood cancer survivors treated with anthracyclines* , 2015, Cardiology in the Young.

[20]  James D. Thomas,et al.  Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study. , 2015, Journal of the American College of Cardiology.

[21]  G. Curigliano,et al.  Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy , 2015, Circulation.

[22]  P. Douglas,et al.  Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level. , 2015, Journal of the American College of Cardiology.

[23]  J. Raemaekers,et al.  Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. , 2015, JAMA internal medicine.

[24]  M. Shah.  Update on metastatic gastric and esophageal cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Morschhauser,et al.  Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma , 2015, Expert opinion on drug safety.

[26]  S. Goldhaber,et al.  Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer , 2015, Thrombosis and Haemostasis.

[27]  G. Filippatos,et al.  EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology. , 2015, European heart journal cardiovascular Imaging.

[28]  P. Nathan,et al.  Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. , 2015, The Lancet. Oncology.

[29]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[30]  Sarah C. Darby,et al.  Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma , 2015, Journal of the National Cancer Institute.

[31]  M. Citron,et al.  Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Gary H Lyman,et al.  Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  G. Armstrong,et al.  Screening for cardiac autonomic dysfunction among Hodgkin lymphoma survivors treated with thoracic radiation. , 2015, Journal of the American College of Cardiology.

[34]  Kevin C Oeffinger,et al.  Individual prediction of heart failure among childhood cancer survivors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Valent,et al.  Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. , 2015, Blood.

[36]  G. Pedrizzetti,et al.  Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[37]  M. Humbert,et al.  See related Commentary on page 302 CARDIOVASCULAR , PULMONARY , AND RENAL PATHOLOGY Chemotherapy-Induced Pulmonary Hypertension Role of Alkylating Agents , 2015 .

[38]  J. Tamargo,et al.  Cancer Chemotherapy and Cardiac Arrhythmias: A Review , 2015, Drug Safety.

[39]  Aspire Investigators,et al.  Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma , 2015 .

[40]  M. Breteler,et al.  Prevalence of cerebral small-vessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Dogan,et al.  Protective effects of spironolactone against anthracycline‐induced cardiomyopathy , 2015, European journal of heart failure.

[42]  T. Choueiri,et al.  Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. , 2014, Critical reviews in oncology/hematology.

[43]  P. Charron,et al.  The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS) , 2015 .

[44]  Michael L. Wang,et al.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.

[45]  P. Evans,et al.  The UK HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[46]  Michael S. Ewer,et al.  Cardiotoxicity of anticancer treatments , 2015, Nature Reviews Cardiology.

[47]  G. Lip,et al.  Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes , 2014, PloS one.

[48]  Jose Luis Zamorano,et al.  The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS) , 2014 .

[49]  P. Douglas,et al.  Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: a report from the childhood cancer survivor study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  H. Liebman,et al.  Approach to the management of incidental venous thromboembolic events in patients with cancer. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[51]  M. Cerqueira,et al.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2014, European heart journal cardiovascular Imaging.

[52]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[53]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[54]  Yang Yao,et al.  Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta‐analysis of 36 clinical trials , 2014, British journal of clinical pharmacology.

[55]  K. Vistisen,et al.  A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity , 2014, BMC Pharmacology and Toxicology.

[56]  P. Vejpongsa,et al.  Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. , 2014, Journal of the American College of Cardiology.

[57]  P. Ponikowski,et al.  Vitamin b12 and folate deficiency: prevalence, clinical correlates and outcome in chronic heart failure , 2014 .

[58]  R. Dweik,et al.  Imatinib in Pulmonary Arterial Hypertension: C-Kit Inhibition , 2014, Pulmonary circulation.

[59]  M. Kohli,et al.  Evaluation and management of patients with heart disease and cancer: cardio-oncology. , 2014, Mayo Clinic proceedings.

[60]  L. Minasian,et al.  Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. , 2014, Journal of the National Cancer Institute.

[61]  M. Dew,et al.  Correlates of Positive Health Behaviors in Cancer Survivors: Results from the 2010 LIVESTRONG Survey , 2014, Journal of psychosocial oncology.

[62]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[63]  A. Yan,et al.  Chemotherapy-induced cardiotoxicity: detection, prevention, and management. , 2014, The Canadian journal of cardiology.

[64]  G. Demetri,et al.  Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. , 2014, European journal of cancer.

[65]  M. Dowsett,et al.  Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Lara A. Kahale,et al.  Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. , 2014, The Cochrane database of systematic reviews.

[67]  Paaladinesh Thavendiranathan,et al.  Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. , 2014, Journal of the American College of Cardiology.

[68]  S. Rosen,et al.  Cardiovascular toxicity of biologic agents for cancer therapy. , 2014, Oncology.

[69]  I. Mahé,et al.  New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients , 2014, Therapeutics and clinical risk management.

[70]  D. Farge,et al.  Therapy for cancer-related thromboembolism. , 2014, Seminars in oncology.

[71]  L. Ferrari,et al.  Arterial hypertension and cancer , 2014, International journal of cancer.

[72]  R. Talamini,et al.  Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  E. Deconinck,et al.  Incidence and risk‐factors of CHOP/R‐CHOP‐related cardiotoxicity in patients with aggressive non‐Hodgkin's lymphoma , 2014, Journal of clinical pharmacy and therapeutics.

[74]  G. Filippatos,et al.  Insights into onco-cardiology: atrial fibrillation in cancer. , 2014, Journal of the American College of Cardiology.

[75]  R. Ferrari,et al.  Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. , 2014, European heart journal.

[76]  Randolph P. Martin,et al.  Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. , 2014, Journal of the American College of Cardiology.

[77]  T. Marwick,et al.  Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. , 2014, European heart journal cardiovascular Imaging.

[78]  W. Gradishar,et al.  Burnout and career satisfaction among US oncologists. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  D. Pérennou,et al.  Thromboses itératives de pontages artériels et cancer : à propos de trois cas , 2014 .

[80]  K. Harrington,et al.  Clinical features of radiation-induced carotid atherosclerosis. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[81]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[82]  C. Gross,et al.  Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer , 2014, Journal of the American Heart Association.

[83]  R. Witteles,et al.  Cancer therapy-induced left ventricular dysfunction: interventions and prognosis. , 2013, Journal of cardiac failure.

[84]  D. Pérennou,et al.  [Arterial bypass iterative thrombosis and cancer: three cases]. , 2014, Journal des maladies vasculaires.

[85]  A. Khorana,et al.  Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. , 2014, The American journal of medicine.

[86]  Jeroen J. Bax,et al.  ESC Guidelines on the diagnosis and management of acute pulmonary embolism , 2014 .

[87]  C. Hudis,et al.  Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer , 2014, Breast Cancer Research and Treatment.

[88]  J. Xu,et al.  Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis , 2013, European Journal of Clinical Pharmacology.

[89]  Kirsten Vistisen,et al.  Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. , 2013, Cancer treatment reviews.

[90]  Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer , 2013, Journal of experimental & clinical cancer research : CR.

[91]  Susan Cheng,et al.  Cancer-drug discovery and cardiovascular surveillance. , 2013, The New England journal of medicine.

[92]  J. Vonk,et al.  Endothelial damage in long-term survivors of childhood cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  S. Flamm,et al.  Cardiac MRI in the Assessment of Cardiac Injury and Toxicity From Cancer Chemotherapy: A Systematic Review , 2013, Circulation. Cardiovascular imaging.

[94]  H. Biersack,et al.  Radium-223 in prostate cancer. , 2013, The New England journal of medicine.

[95]  S. Colan,et al.  Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions A Scientific Statement From the American Heart Association , 2013, Circulation.

[96]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[97]  G. Armstrong,et al.  Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  Jeroen J. Bax,et al.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. , 2013, European heart journal.

[99]  B. Khandheria,et al.  Cardioncology: state of the heart. , 2013, International journal of cardiology.

[100]  M. Dowsett,et al.  2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial , 2013, The Lancet.

[101]  G. Raskob,et al.  Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies , 2013, Thrombosis Journal.

[102]  M. Bansal.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013 .

[103]  Yang Yao,et al.  Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. , 2013, British journal of clinical pharmacology.

[104]  Y. Lam,et al.  Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. , 2013, International journal of cardiology.

[105]  S. Wann,et al.  Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. , 2013, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[106]  M. Parmar,et al.  Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. , 2013, The Lancet. Oncology.

[107]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[108]  A. Abbate,et al.  Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study. , 2013, International journal of cardiology.

[109]  P. Kowey,et al.  Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. , 2013, The oncologist.

[110]  W. Hundley,et al.  Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. , 2013, JACC. Cardiovascular imaging.

[111]  Christine Y. Lu,et al.  Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function? , 2013, Breast.

[112]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[113]  C. Watson,et al.  Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. , 2013, JAMA.

[114]  J. Mariani,et al.  Cardiac complications of thoracic irradiation. , 2013, Journal of the American College of Cardiology.

[115]  J. Esteve,et al.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013, Journal of the American College of Cardiology.

[116]  D. Lenihan,et al.  Cardiac toxicity in cancer survivors , 2013, Cancer.

[117]  Susan Cheng,et al.  Cardio-Oncology: It Takes Two to Translate , 2013, Science Translational Medicine.

[118]  J. Paramo,et al.  High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients , 2013, Thrombosis and Haemostasis.

[119]  M. Galsky,et al.  Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis , 2013, Journal of Human Hypertension.

[120]  T. Marwick,et al.  Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. , 2013, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[121]  R. Motzer,et al.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[122]  R. Shah,et al.  Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval) , 2013, Drug Safety.

[123]  T. Suter,et al.  Cancer drugs and the heart: importance and management. , 2013, European heart journal.

[124]  R. Schwartz,et al.  Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively , 2013, Journal of Nuclear Cardiology.

[125]  Vinay R. Hosmane,et al.  Frequency of Severe Valvular Disease Caused by Mediastinal Radiation Among Patients Undergoing Valve Surgery in a Community‐Based, Regional Academic Medical Center , 2013, Clinical cardiology.

[126]  Yang Yao,et al.  Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta‐analysis of clinical trials , 2013, British journal of clinical pharmacology.

[127]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[128]  P. Hall,et al.  Risk of ischemic heart disease in women after radiotherapy for breast cancer. , 2013, The New England journal of medicine.

[129]  H. Ghofrani,et al.  Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study , 2013, Circulation.

[130]  Tevfik F Ismail,et al.  Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. , 2013, JAMA.

[131]  B. Kühn,et al.  ERBB2 inhibition and heart failure. , 2013, The New England journal of medicine.

[132]  T. Marwick,et al.  Cardioprotective Effect of &bgr;-Adrenoceptor Blockade in Patients With Breast Cancer Undergoing Chemotherapy: Follow-Up Study of Heart Failure , 2013, Circulation. Heart failure.

[133]  G. Armstrong,et al.  Increased tricuspid regurgitant jet velocity by Doppler echocardiography in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  M. Hudson,et al.  American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  S. Srinivas,et al.  The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. , 2013, JACC. Heart failure.

[136]  Cam Patterson,et al.  Proteotoxicity and cardiac dysfunction--Alzheimer's disease of the heart? , 2013, The New England journal of medicine.

[137]  J. Hainsworth,et al.  Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  T. Marwick,et al.  Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. , 2013, Journal of the American College of Cardiology.

[139]  A. Khorana,et al.  International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer , 2013, Journal of thrombosis and haemostasis : JTH.

[140]  M. Zibelman,et al.  Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer , 2013 .

[141]  J. Hainsworth,et al.  Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. , 2013, The Lancet. Oncology.

[142]  B. Gersh,et al.  ESC guidelines on the management of stable coronary artery disease — addenda The Task Force on the management of stable coronary artery disease of the European Society of Cardiology , 2013 .

[143]  C. Flowers,et al.  Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[145]  T. Marwick,et al.  Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. , 2012, Journal of the American College of Cardiology.

[146]  J. Mackey,et al.  Contemporary Reviews in Cardiovascular Medicine Cancer Therapy – Induced Cardiac Toxicity in Early Breast Cancer Addressing the Unresolved Issues , 2012 .

[147]  F. Amant,et al.  Chemotherapy during pregnancy: effect of anthracyclines on fetal and maternal cardiac function , 2012, Acta obstetricia et gynecologica Scandinavica.

[148]  J. Xue,et al.  Dosimetric investigation of accelerated partial breast irradiation (APBI) using CyberKnife. , 2012, Medical physics.

[149]  E. Yeh,et al.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.

[150]  D. Lenihan,et al.  Late cardiac effects of cancer treatment. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  O. Alfieri,et al.  Guidelines on the management of valvular heart disease (version 2012). , 2012, European heart journal.

[152]  A. Goldhirsch,et al.  Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[153]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[154]  L. Allen,et al.  Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study , 2012, Journal of the National Cancer Institute.

[155]  Randolph P. Martin,et al.  Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab , 2012, Circulation. Cardiovascular imaging.

[156]  C. Snyder,et al.  Exercise interventions on health-related quality of life for people with cancer during active treatment. , 2012, The Cochrane database of systematic reviews.

[157]  S. Flamm,et al.  Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  F. Amant,et al.  Effects of chemotherapy during pregnancy on the maternal and fetal heart , 2012, Prenatal diagnosis.

[159]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[160]  M. Humbert,et al.  Résultats tardifs de la commissurotomie mitrale percutanée à 20 ans Création et validation d ’ un score de risque prédisant les résultats fonctionnels à long terme à partir d ’ une série de 912 patients , 2012 .

[161]  Delong Liu,et al.  Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis , 2012, Experimental Hematology & Oncology.

[162]  A. Poprach,et al.  Cardiac Toxicity of Targeted Therapies Used in the Treatment for Solid Tumours: A Review , 2012, Cardiovascular Toxicology.

[163]  L. Moja,et al.  Trastuzumab containing regimens for early breast cancer. , 2012, The Cochrane database of systematic reviews.

[164]  J. Baselga,et al.  Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[165]  R. Gralla,et al.  Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial , 2012, Supportive Care in Cancer.

[166]  J. Baselga,et al.  Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[167]  J. Daubert,et al.  Characteristics and long-term outcome of non-immune isolated atrioventricular block diagnosed in utero or early childhood: a multicentre study. , 2012, European heart journal.

[168]  M. Bots,et al.  Stenting Versus Surgery in Patients With Carotid Stenosis After Previous Cervical Radiation Therapy: Systematic Review and Meta-Analysis , 2012, Stroke.

[169]  Ming-Hui Chen,et al.  Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. , 2012, American heart journal.

[170]  Raimund Erbel,et al.  [2011 ESC guidelines on the diagnosis and treatment of peripheral artery diseases]. , 2012, Revue medicale de Liege.

[171]  Jie Tang,et al.  Prior image constrained compressed sensing: implementation and performance evaluation. , 2011, Medical physics.

[172]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[173]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[174]  Ralph DiGaetano,et al.  Hypertension and Risk of Renal Cell Carcinoma Among White and Black Americans , 2011, Epidemiology.

[175]  Marc Buyse,et al.  Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.

[176]  D. Feldman,et al.  High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[177]  M. Copur,et al.  An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. , 2011, Clinical colorectal cancer.

[178]  C. Plummer,et al.  Ischemic Stroke and Transient Ischemic Attack After Head and Neck Radiotherapy: A Review , 2011, Stroke.

[179]  J. Mackey,et al.  Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. , 2011, Circulation.

[180]  P. Hall,et al.  Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[181]  B. Ky,et al.  Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy. , 2011, Heart failure clinics.

[182]  A. Khorana.  Risk assessment and prophylaxis for VTE in cancer patients. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[183]  R. Wimalasundera,et al.  Uterine torsion in a monochorionic diamniotic (MCDA) twins pregnancy , 2011, Prenatal diagnosis.

[184]  J. Jassem,et al.  Cardiovascular effects of systemic cancer treatment. , 2011, Cancer treatment reviews.

[185]  S. Iacobelli,et al.  Arterial thrombosis in ambulatory cancer patients treated with chemotherapy. , 2011, Thrombosis research.

[186]  M. Beer,et al.  Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin's disease. , 2011, International Journal of Radiation Oncology, Biology, Physics.

[187]  M. Aapro,et al.  Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[188]  Munir Pirmohamed,et al.  Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology , 2011, European journal of heart failure.

[189]  J. Beijnen,et al.  Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. , 2010, Gynecologic oncology.

[190]  R. Carlson,et al.  Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? , 2010, Journal of the American College of Cardiology.

[191]  S. Fosså,et al.  Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[192]  J. Monsuez,et al.  Cardiac side-effects of cancer chemotherapy. , 2010, International journal of cardiology.

[193]  N. Jaffe,et al.  COMPARISON OF DOXORUBICIN CARDIOTOXICITY IN PEDIATRIC SARCOMA PATIENTS WHEN GIVEN WITH DEXRAZOXANE VERSUS AS CONTINUOUS INFUSION , 2010, Pediatric hematology and oncology.

[194]  F. Veglia,et al.  Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[195]  C. Lim,et al.  Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? , 2010, Progress in cardiovascular diseases.

[196]  Giuseppe Curigliano,et al.  Cardiac toxicity from systemic cancer therapy: a comprehensive review. , 2010, Progress in cardiovascular diseases.

[197]  D. Cardinale,et al.  Role of biomarkers in chemotherapy-induced cardiotoxicity. , 2010, Progress in cardiovascular diseases.

[198]  C. Cipolla,et al.  The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. , 2010, Progress in cardiovascular diseases.

[199]  Michael S. Ewer,et al.  Cardiotoxicity of anticancer treatments: what the cardiologist needs to know , 2010, Nature Reviews Cardiology.

[200]  M. Maitland,et al.  Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors , 2010, Journal of the National Cancer Institute.

[201]  Neelima Penugonda.  Cardiac MRI in Infiltrative Disorders: A Concise Review , 2010, Current cardiology reviews.

[202]  T. Choueiri,et al.  Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[203]  Shenhong Wu,et al.  Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. , 2010, American journal of hypertension.

[204]  J. Bourhis,et al.  Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[205]  Adam P Dicker,et al.  Radiation dose-volume effects in the brain. , 2010, International journal of radiation oncology, biology, physics.

[206]  B. Wolffenbuttel,et al.  The metabolic syndrome in cancer survivors. , 2010, The Lancet. Oncology.

[207]  F. Amant,et al.  Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[208]  F. Veglia,et al.  Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. , 2010, Journal of the American College of Cardiology.

[209]  S. De Flora,et al.  Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention , 2010, Journal of the National Cancer Institute.

[210]  G. Grana,et al.  Breast Cancer During Pregnancy: Maternal and Fetal Outcomes , 2010, Cancer journal.

[211]  B. Iung,et al.  Radiotherapy-induced mitral stenosis: a three-dimensional perspective. , 2010, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[212]  H. Caron,et al.  Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.

[213]  Vitali Moiseenko,et al.  Radiation dose-volume effects in the heart. , 2010, International journal of radiation oncology, biology, physics.

[214]  Y. Arima,et al.  Sorafenib-induced acute myocardial infarction due to coronary artery spasm. , 2009, Journal of cardiology.

[215]  A. Khorana,et al.  Assessing risk of venous thromboembolism in the patient with cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[216]  S. Barni,et al.  Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. , 2009, The Lancet. Oncology.

[217]  Liang Xiu,et al.  Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase II , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  H. Hurwitz,et al.  Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression , 2009, Hypertension.

[219]  Richard B. Thompson,et al.  Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise Training , 2009, Clinical Cancer Research.

[220]  R. Newton,et al.  Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise. , 2009, Journal of science and medicine in sport.

[221]  M. D. De Bruin,et al.  Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. , 2008, Journal of the National Cancer Institute.

[222]  E. Yeh,et al.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.

[223]  G. Biondi-Zoccai,et al.  Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study. , 2009, International journal of cardiology.

[224]  D. Mulrooney,et al.  Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[225]  M. Piccart-Gebhart,et al.  Cardiac toxicity with anti-HER-2 therapies-what have we learned so far? , 2009, Targeted Oncology.

[226]  S. Glück,et al.  A woman's heart , 2009, Cancer.

[227]  J. Soria,et al.  Review Management of Hypertension in Angiogenesis Inhibitor-treated Patients , 2022 .

[228]  G. Kenyon.  Experts call for urgent skin-cancer awareness campaigns in Chile. , 2009, The Lancet. Oncology.

[229]  A. Wardley,et al.  Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring , 2009, British Journal of Cancer.

[230]  K. Stergiopoulos,et al.  Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis , 2009, Acta oncologica.

[231]  P. Sengupta,et al.  Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. , 2009, The oncologist.

[232]  M. Ewer.  The Impact of Adjuvant Endocrine Therapy on Cardiovascular Health , 2009 .

[233]  W. Gradishar,et al.  American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[234]  M. Saif,et al.  Fluoropyrimidine-associated cardiotoxicity: revisited. , 2009, Expert opinion on drug safety.

[235]  R. Bashir,et al.  Radiation‐induced peripheral artery disease , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[236]  Piotr Pruszczyk,et al.  Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism , 2008 .

[237]  Torben Skovsgaard,et al.  New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. , 2008, Journal of the National Cancer Institute.

[238]  D. Nochy,et al.  VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.

[239]  W. Tsai,et al.  Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[240]  M. Chen,et al.  Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics , 2008, Circulation.

[241]  E. Perez,et al.  Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. , 2008, Mayo Clinic proceedings.

[242]  A. Kakkar.  Venous thromboembolism prophylaxis and treatment in patients with cancer. , 2008, Clinical advances in hematology & oncology : H&O.

[243]  D. Lenihan,et al.  Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[244]  D. Neuberg,et al.  Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[245]  A. Kudelka,et al.  Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. , 2008, The Lancet. Oncology.

[246]  M. Ewer,et al.  Cardiotoxicity Profile of Trastuzumab , 2008, Drug safety.

[247]  H. Dickinson,et al.  Cardioprotective interventions for cancer patients receiving anthracyclines. , 2008, The Cochrane database of systematic reviews.

[248]  L. Marks,et al.  Prospective assessment of radiotherapy‐associated cardiac toxicity in breast cancer patients: Analysis of data 3 to 6 years after treatment , 2007, Cancer.

[249]  J. Bergh,et al.  Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[250]  J. Goodwin,et al.  Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[251]  F. Kabbinavar,et al.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.

[252]  L. Siu,et al.  Molecularly targeted oncology therapeutics and prolongation of the QT interval. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[253]  Wei-Ting Hwang,et al.  Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[254]  J. Syrios,et al.  Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study , 2007, Journal of Cancer Research and Clinical Oncology.

[255]  E. Stickeler,et al.  Cardiac safety of pegylated liposomal doxorubicin (PLD) in combination with trastuzumab (T) in patients with metastatic breast cancer (MBC): Results from a multicenter phase II study , 2007 .

[256]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[257]  R. A. Etten,et al.  Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.

[258]  M. V. van Herk,et al.  Three-dimensional heart dose reconstruction to estimate normal tissue complication probability after breast irradiation using portal dosimetry. , 2007, Medical physics.

[259]  J. Blay,et al.  Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. , 2007, European journal of cancer.

[260]  H. Bartelink,et al.  Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. , 2007, Journal of the National Cancer Institute.

[261]  A. Hart,et al.  Late cardiotoxicity after treatment for Hodgkin lymphoma. , 2007, Blood.

[262]  L. Constine,et al.  Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[263]  David Cameron,et al.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.

[264]  Helmut Baumgartner,et al.  Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology , 2007 .

[265]  Giovanni Martinelli,et al.  Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition , 2006, Circulation.

[266]  F. Holmes,et al.  Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[267]  T. Merchant,et al.  Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. , 2006, International journal of radiation oncology, biology, physics.

[268]  A. Dogan,et al.  Protective effects of carvedilol against anthracycline-induced cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[269]  Kevin C Oeffinger,et al.  Chronic health conditions in adult survivors of childhood cancer. , 2006, The New England journal of medicine.

[270]  D. Webb,et al.  Effect of Regular Phosphodiesterase Type 5 Inhibition in Hypertension , 2006, Hypertension.

[271]  T. Fojo,et al.  Challenges of Evaluating the Cardiac Effects of Anticancer Agents , 2006, Clinical Cancer Research.

[272]  L. Gianni,et al.  Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies , 2006, Journal of Pharmacology and Experimental Therapeutics.

[273]  F. Rickles.  Mechanisms of Cancer-Induced Thrombosis in Cancer , 2006, Pathophysiology of Haemostasis and Thrombosis.

[274]  M. Espié,et al.  Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[275]  S. Pakakasama,et al.  Pulmonary Arterial Hypertension after Childhood Cancer Therapy and Bone Marrow Transplantation , 2006, Cardiology.

[276]  Tufia C Haddad,et al.  Chemotherapy-induced thrombosis. , 2006, Thrombosis research.

[277]  K. Ohta,et al.  Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone , 2005, Cancer.

[278]  Greg Yothers,et al.  Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[279]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[280]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[281]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[282]  Wesley E Bolch,et al.  Accounting for beta-particle energy loss to cortical bone via paired-image radiation transport (PIRT). , 2005, Medical physics.

[283]  S. Lippman,et al.  Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[284]  L. Marks,et al.  Cardiac toxicity following thoracic radiation. , 2005, Seminars in oncology.

[285]  L. F. Fajardo.  The pathology of ionizing radiation as defined by morphologic patterns* , 2005, Acta oncologica.

[286]  J. Emery,et al.  Repeat sudden unexpected and unexplained infant deaths: natural or unnatural? , 2005, The Lancet.

[287]  L. Rutqvist,et al.  Detection of radiation-induced myocardial damage by technetium-99m sestamibi scintigraphy , 1997, European Journal of Nuclear Medicine.

[288]  Gwyn McClelland.  Survivors , 1891, The Hospital.

[289]  S. Lipsitz,et al.  The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. , 2004, The New England journal of medicine.

[290]  G. Martinelli,et al.  Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.

[291]  G. Salles,et al.  Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[292]  Raimund Erbel,et al.  Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. , 2004, European heart journal.

[293]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[294]  Xinxin Guo,et al.  Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes* , 2004, Journal of Biological Chemistry.

[295]  C. Pepine,et al.  Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. , 2003, JAMA.

[296]  S. Hancock,et al.  Asymptomatic cardiac disease following mediastinal irradiation. , 2003, Journal of the American College of Cardiology.

[297]  D. Horstkotte,et al.  Echocardiographic features of radiation-associated valvular disease. , 2003, The American journal of cardiology.

[298]  Robert M Califf,et al.  What clinicians should know about the QT interval. , 2003, JAMA.

[299]  D P Dearnaley,et al.  Cardiovascular disease as a long-term complication of treatment for testicular cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[300]  B. Zaret,et al.  Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era , 2003, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[301]  M. Sigmund,et al.  Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[302]  Lyndsay Harris,et al.  Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.

[303]  R. Munden,et al.  Coronary artery dosimetry in intact left breast irradiation. , 2001, Cancer journal.

[304]  S. Soignet,et al.  United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[305]  F. Holmes,et al.  Pharmacokinetic profiles of doxorubicin in combination with taxanes. , 2001, Seminars in oncology.

[306]  L. Harrold,et al.  Use of paclitaxel in patients with pre‐existing cardiomyopathy: A review of our experience , 2001, International journal of cancer.

[307]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[308]  M Gent,et al.  Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[309]  S. Groshen,et al.  Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[310]  G. Martinelli,et al.  Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. , 2000, Journal of the American College of Cardiology.

[311]  D J Pennell,et al.  Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? , 2000, European heart journal.

[312]  W. Butler,et al.  The effect of constipation on rectal dosimetry following prostate brachytherapy. , 2000, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[313]  R H Hruban,et al.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. , 2000, The New England journal of medicine.

[314]  M. Adamcová,et al.  Anthracycline-induced cardiotoxicity. , 2000, Acta medica.

[315]  A. Wilde,et al.  Pacemaker-implantation prevents sudden death in a large family with LQT3 , 1999 .

[316]  K. Tolba,et al.  Cardiotoxicity of cancer therapy. , 1999, Cancer investigation.

[317]  R. Virmani,et al.  Comparative pathology: radiation-induced coronary artery disease in man and animals. , 1998, Seminars in interventional cardiology : SIIC.

[318]  S. Swain,et al.  Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[319]  S. Swain,et al.  Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[320]  L. Zeiger,et al.  Selective tumor irradiation by infusional brachytherapy in nonresectable pancreatic cancer: a phase I study. , 1996, International journal of radiation oncology, biology, physics.

[321]  C. Tibaldi,et al.  Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[322]  W. Edwards,et al.  Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. , 1996, Human pathology.

[323]  R. Mertelsmann,et al.  BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[324]  P. Rubin,et al.  Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. , 1996, International journal of radiation oncology, biology, physics.

[325]  A. Caraceni,et al.  Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[326]  J. R. Stewart,et al.  Radiation injury to the heart. , 1995, International journal of radiation oncology, biology, physics.

[327]  R. Jenni,et al.  Cardiac lesions after mediastinal irradiation for Hodgkin's disease. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[328]  S L Hancock,et al.  Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. , 1993, JAMA.

[329]  F. Orzan,et al.  Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. , 1993, British heart journal.

[330]  V. Ferrans,et al.  ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[331]  P. Steinherz,et al.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.

[332]  E. Cook,et al.  Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[333]  D. Spelbring,et al.  Estimation of doses to heart, coronary arteries, and spinal cord in mediastinal irradiation for Hodgkin's disease. , 1991, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[334]  M. Albertsson,et al.  Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. , 1990, Acta oncologica.

[335]  H. Bruckner,et al.  Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers. , 1988, The American journal of medicine.

[336]  W. C. Sheldon,et al.  Clinical and angiographic features of coronary artery disease after chest irradiation. , 1987, The American journal of cardiology.

[337]  F. Torti,et al.  Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. , 1983, Annals of internal medicine.

[338]  J. Doroshow.  Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. , 1983, Cancer research.

[339]  P. Wiernik,et al.  Cardiac disease after radiation therapy for Hodgkin's disease: analysis of 48 patients. , 1983, The American journal of cardiology.

[340]  O. Matsuo,et al.  Determination of α2-plasmin inhibitor in body fluids , 1982 .

[341]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[342]  J. Gottdiener,et al.  Cardiotoxicity associated with high-dose cyclophosphamide therapy. , 1981, Archives of internal medicine.

[343]  Michael V. Green,et al.  Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. , 1981, Annals of internal medicine.

[344]  W. Roberts,et al.  Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. , 1981, The American journal of medicine.

[345]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[346]  Randolph P. Martin,et al.  Early anthracycline cardiotoxicity. , 1978, The American journal of medicine.

[347]  G. Wortzman,et al.  Chronic damage to medium and large arteries following irradiation. , 1974, Journal of the Canadian Association of Radiologists.